Long-term efficacy of afatinib in a patient with squamous cell carcinoma of the lung and multiple ERBB family aberrations: afatinib in ERBB+ lung squamous cell carcinoma

In the phase 3 LUX-Lung 8 study, the ERBB family blocker, afatinib, significantly prolonged progression-free survival and overall survival relative to erlotinib in patients with relapsed/refractory squamous cell carcinoma of the lung. We describe the case of a 53-year-old Asian male enrolled in LUX-...

Descripción completa

Detalles Bibliográficos
Autores principales: Jian, Hong, Han, Yuchen, Yu, Yongfeng, Lu, Shun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6727938/
https://www.ncbi.nlm.nih.gov/pubmed/31283542
http://dx.doi.org/10.1097/CAD.0000000000000813

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6727938/
https://www.ncbi.nlm.nih.gov/pubmed/31283542
http://dx.doi.org/10.1097/CAD.0000000000000813

Ejemplares similares